

Approved



**Dominican Republic**  
**Country Operational Plan**  
**FY 2016**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
USAID		1,862,312	5,424,618	7,286,930	601,903	7,888,833
DOD		75,278		75,278	18,666	93,944
HHS/CDC	387,500	7,129,723		7,517,223	0	7,517,223
<b>Total</b>	<b>387,500</b>	<b>9,067,313</b>	<b>5,424,618</b>	<b>14,879,431</b>	<b>620,569</b>	<b>15,500,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency			On Hold Amount	Total
	DOD	HHS/CDC	USAID		
HBHC	6,359	271,423	259,767	0	537,549
HLAB		217,050		0	217,050
HMBL		0		0	0
HTXS		2,064,776	2,445,622	0	4,510,398
HVCT	6,359	1,161,198	791,936	0	1,959,493
HVMS	43,483	1,680,787	328,628	0	2,052,898
HVOP	6,359	498,112	919,973	0	1,424,444
HVSI	6,359	834,982	533,124	0	1,374,465
HVTB		151,722		0	151,722
OHSS	6,359	637,173	2,007,880	0	2,651,412
	<b>75,278</b>	<b>7,517,223</b>	<b>7,286,930</b>	<b>0</b>	<b>14,879,431</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	482,385	0
HVTB	125,000	0
<b>Total Technical Area Planned Funding:</b>	<b>607,385</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	182,329	0
HVSI	1,200,000	0
OHSS	2,462,940	0
<b>Total Technical Area Planned Funding:</b>	<b>3,845,269</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	0	0
HVCT	1,802,670	0
HVOP	1,345,622	0
<b>Total Technical Area Planned Funding:</b>	<b>3,148,292</b>	<b>0</b>

#### Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	4,189,472	0
<b>Total Technical Area Planned Funding:</b>	<b>4,189,472</b>	<b>0</b>

Approved





### Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	44,813
	Total number of people in the target population	230,609
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
Denominator: Age/sex: 50+ Male		
Denominator: Age/sex: 10-14		



	Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	29,128
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	15,685
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,887
	Total estimated number of key population in the catchment area	78,736
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of	



	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,256
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	631



	required)	
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	44,055
	By key population type:	



	Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	34,681
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	



	By New Client Status: RReturning beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	89,627
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
Test Result by Age and Sex: Positive: 10-14 Female		
Test Result by Age and Sex: Positive: 15-19 Female		



	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	50,047
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH	39,580



	HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,567
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,040
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	37,361
	Service Delivery Point (Community): Other	11,598
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	



	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	40,667
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	



	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	



	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
Test Result by Age and Sex: Positive: 10-14 Female		
Test Result by Age and Sex:		



	Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0
	Aggregated Age/sex - USE WITH	



	HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	726
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	726
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community)	



	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	0
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility):	



	Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by	



	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
GEND_GBV_DSD	Number of people receiving post-GBV care	60
	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	30
	Age/Sex: 25-49 Female	30
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	60
	By type of service: Sexual Violence (Post-Rape Care)	
By PEP service provision (related to sexual violence services provided)		
Age/Sex: 15-19 Female		



	Age/Sex: 15-19 male	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	13,374
	Screened for TB by Age/Sex:<15 Male	
	Screened for TB by Age/Sex: 15+ Male	5,469
	Screened for TB by Age/Sex:<15 Female	
	Screened for TB by Age/Sex: 15+ Female	5,463
	Screen Result: Screened Positive for TB	1,338
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,207
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,207
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	14,860



	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 15+ Male	7,434
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	7,427
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	14,861
	Sum of Aggregated Age/Sex disaggregates	14,861
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,085
	By Age/Sex: <1	
	By Age/Sex: 1-9	



	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	3,045
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	3,040
	Sum of Aggregated Age/Sex disaggregates	6,085
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children	



	newly enrolled on antiretroviral therapy (ART)	
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	475
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	474
	Sum of Age/Sex disaggregates	949
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex:	



	<15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex disaggregates	
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	9,418
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	11,888
	Numerator: Indication: Routine	9,103
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	



	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	



	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	11,102
	Denominator: Indication: Targeted	



	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	



	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	



	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	4,600
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	4,591
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	5,923
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	5,915
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1
	Number of adult and pediatric ART patients with a viral load result	1



	documented in the patient medical record and /or laboratory records in the past 12 months.	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication:	



	20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	317



	Numerator: Indication: Targeted	0
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	877
	Denominator: Indication: Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by	



	Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex	



	by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	113
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	118
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	26
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	28
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after	n/a



	initiation of antiretroviral therapy	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,457
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,773
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total	



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,732
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,725
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,389
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,384
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	81
	HIV serologic/diagnostic testing: Number of laboratories that	12



	participate in this PT program	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
	CD4: Number of laboratories that perform this testing	1
	CD4: Number of laboratories that participate in this PT program	1
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	Early infant diagnostics: Number of laboratories that perform this testing	
	Early infant diagnostics: Number of laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	HIV viral load: Number of laboratories that perform this testing	1
	HIV viral load: Number of laboratories that participate in this PT program	1
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	



	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful	0



	passing criteria in this PT program	
	CD4: Number of laboratories that participate in this PT program	0
	CD4: Number of laboratories that perform this testing	0
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that perform this testing	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	HIV viral load: Number of laboratories that participate in this PT program	0
	HIV viral load: Number of laboratories that perform this testing	0



	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7575	University of North Carolina	University	U.S. Agency for International Development	GHP-USAID	350,000
11957	Foundation for Innovative New Diagnostics	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
11972	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-USAID	746,141
12928	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-USAID	258,300
13334	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13507	Ministry of Health, Dominican Republic	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	0



			Control and Prevention		
14722	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
17002	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State, GHP-USAID	2,261,471
17474	Population Services International	NGO	U.S. Department of Defense	GHP-State	0
17527	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	125,000
17561	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	375,000
17562	Centro de Orientacion e Investigacion Integral	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	729,298
17608	Population Services International	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	2,119,836



			for Disease Control and Prevention		
17752	Research Triangle International	Private Contractor	U.S. Department of Defense	GHP-State	0
17762	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	1,418,747
17915	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	999,395
17916	TBD	TBD	Redacted	Redacted	Redacted
18388	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	182,329
18390	TBD	TBD	Redacted	Redacted	Redacted
18413	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-USAID	400,000
18414	TBD	TBD	Redacted	Redacted	Redacted
18461	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Agency for International Development	GHP-State, GHP-USAID	200,000
18462	Population Services International	NGO	U.S. Agency for International Development	GHP-USAID	350,000

Approved





## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 7575</b>	<b>Mechanism Name: MEASURE Evaluation Phase IV</b>
Funding Agency: USAID	Procurement Type: USG Core
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 350,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 350,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	350,000

### Cross-Cutting Budget Attribution(s)

Key Populations: FSW	50,000
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	50,000
Focus Area:	Monitoring and evaluation of MSM/TG programs

### Budget Code Information

<b>Mechanism ID:</b> 7575			
<b>Mechanism Name:</b> MEASURE Evaluation Phase IV			
<b>Prime Partner Name:</b> University of North Carolina			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Approved



Governance and Systems	HVSI	350,000	0
------------------------	------	---------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 11957</b>	<b>Mechanism Name: Strengthening clinical laboratories in the Dominican Republic</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Innovative New Diagnostics	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	11957		
<b>Mechanism Name:</b>	Strengthening clinical laboratories in the Dominican Republic		
<b>Prime Partner Name:</b>	Foundation for Innovative New Diagnostics		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 11972</b>	<b>Mechanism Name: CAPACITY PLUS</b>
Funding Agency: USAID	Procurement Type: USG Core
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 746,141</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 746,141</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	746,141

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	746,141
----------------------------	---------

**Budget Code Information**



<b>Mechanism ID:</b> 11972			
<b>Mechanism Name:</b> CAPACITY PLUS			
<b>Prime Partner Name:</b> IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	412,940	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	333,201	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,000
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,000
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,000
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	50
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	50
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	2,000

### Implementing Mechanism Details

<b>Mechanism ID:</b> 12928	<b>Mechanism Name:</b> MSH/SIAPS
Funding Agency: USAID	Procurement Type: USG Core
Prime Partner Name: Management Sciences for Health	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 258,300</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 258,300</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	258,300

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 12928</b>			
<b>Mechanism Name: MSH/SIAPS</b>			
<b>Prime Partner Name: Management Sciences for Health</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	175,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	83,300	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
TX_PVLS_TA	Denominator: Indication: Routine	3



**Implementing Mechanism Details**

<b>Mechanism ID: 13334</b>	<b>Mechanism Name: Increasing the Capacity to Provide HIV Prevention Services to Mobile Populations in the Dominican Republic</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13334		
<b>Mechanism Name:</b>	Increasing the Capacity to Provide HIV Prevention Services to Mobile Populations in the Dominican Republic		
<b>Prime Partner Name:</b>	Population Services International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13507</b>	<b>Mechanism Name: Strengthening Dominican Republic Public Ministry of Health in the Areas of Epidemiology, Monitoring and Evaluation, Tuberculosis, Blood Safety, Prevention and Laboratory</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Dominican Republic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC
<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>13507</b>
<b>Mechanism Name:</b>	<b>Strengthening Dominican Republic Public Ministry of Health in the</b>
<b>Prime Partner Name:</b>	<b>Areas of Epidemiology, Monitoring and Evaluation, Tuberculosis, Blood</b>



Safety, Prevention and Laboratory Ministry of Health, Dominican Republic			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 14722	<b>Mechanism Name:</b> DOD
<b>Funding Agency:</b> DOD	<b>Procurement Type:</b> USG Core

Approved



Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14722		
<b>Mechanism Name:</b>	DOD		
<b>Prime Partner Name:</b>	U.S. Department of Defense (Defense)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)



**Implementing Mechanism Details**

<b>Mechanism ID: 17002</b>	<b>Mechanism Name: ADVANCING PARTNERS AND COMMUNITIES (APC)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,261,471</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,261,471</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	937,411
GHP-USAID	1,324,060

**Cross-Cutting Budget Attribution(s)**

Key Populations: MSM and TG	800,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	800,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers



Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	200,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID: 17002</b>			
<b>Mechanism Name: ADVANCING PARTNERS AND COMMUNITIES (APC)</b>			
<b>Prime Partner Name: John Snow Inc (JSI)</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	119,459	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	250,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	311,715	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVOP	347,502	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,082,795	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,887
KP_PREV_DSD	Total estimated number of key population in the catchment area	78,736
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,256
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	631
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	44,055
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	34,681
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,882



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	22,174
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,708
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	33,882
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	33,882
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,146
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	620
HTC_TST_DSD	Service Delivery Point (Community): Other	11,598
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	22,283
GEND_GBV_DSD	Number of people receiving post-GBV care	31
GEND_GBV_DSD	Age/Sex: 20-24 Female	15
GEND_GBV_DSD	Age/Sex: 25-49 Female	16
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	31
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	6,702
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	3,352
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	3,350
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	669
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	602
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	602
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,447
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,725
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,722
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,447
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,447



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,900
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,450
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,450
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,900
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	4,766
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,957
TX_PVLS_DSD	Numerator: Indication: Routine	4,766
TX_PVLS_DSD	Denominator: Indication: Routine	5,957
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	2,271
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,268
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	2,979
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	2,978
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,865
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,547
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,935
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,930
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	2,275



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,272

**Implementing Mechanism Details**

<b>Mechanism ID: 17474</b>	<b>Mechanism Name: Military HTC and Prevention</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17474		
<b>Mechanism Name:</b>	Military HTC and Prevention		
<b>Prime Partner Name:</b>	Population Services International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17527</b>	<b>Mechanism Name: (DIGECITSS) Improving PMTCT counseling, M&amp;E of the PMTCT program, STI services and surveillance, establish performance management of HIV treatment, and capacity of the National Program to address strategic issues for Key Populations</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 125,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 125,000</b>	
Funding Source	Funding Amount
GHP-State	125,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b>	<b>17527</b>		
<b>Mechanism Name:</b>	<b>(DIGECITSS) Improving PMTCT counseling, M&amp;E of the PMTCT program, STI services and surveillance, establish performance management of HIV treatment, and capacity of the National Program to address strategic issues for Key Populations</b>		
<b>Prime Partner Name:</b>	<b>Ministry of Health (MOH)</b>		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	125,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17561</b>	<b>Mechanism Name: (MOH) Strengthening M&amp;E, FETP capacity, health information systems (HIV, TB, laboratory data, and disease surveillance), Supply of safe blood, and national laboratory improvement plan in the DR MoH</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 375,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 375,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	375,000
-----------	---------

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17561		
<b>Mechanism Name:</b>	(MOH) Strengthening M&E, FETP capacity, health information systems (HIV, TB, laboratory data, and disease surveillance), Supply of safe		
<b>Prime Partner Name:</b>	blood, and national laboratory improvement plan in the DR MoH Ministry of Health (MOH)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	375,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17562</b>	<b>Mechanism Name: Increasing Self Sustainable and Friendly Clinical HIV/STI/TB Services for MSMs and Transgender Individuals in the Dominican Republic</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Centro de Orientacion e Investigacion Integral	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



<b>Total All Funding Sources: 729,298</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 729,298</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	729,298

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17562		
<b>Mechanism Name:</b>	Increasing Self Sustainable and Friendly Clinical HIV/STI/TB Services for MSMs and Transgender Individuals in the Dominican Republic		
<b>Prime Partner Name:</b>	Centro de Orientacion e Investigacion Integral		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	72,933	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	19,630	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	636,735	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	7,985



	months	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,993
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,992
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,985
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	7,985
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	214
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	214
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	7,985
GEND_GBV_DSD	Number of people receiving post-GBV care	20
GEND_GBV_DSD	Age/Sex: 20-24 Female	10
GEND_GBV_DSD	Age/Sex: 25-49 Female	10
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	4,091
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	825
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	824
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	410
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	370
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	370
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,545
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,273
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,272
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,545
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,545



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,833
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	916
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	917
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,833
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,909
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,636
TX_PVLS_DSD	Numerator: Indication: Routine	2,593
TX_PVLS_DSD	Denominator: Indication: Routine	2,849
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,455
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	1,454
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,819
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,817
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,305
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,711
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,153
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,152
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	1,356



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,355

**Implementing Mechanism Details**

<b>Mechanism ID: 17608</b>	<b>Mechanism Name: Improving HIV/STI/TB Prevention, Treatment and Care Services for Mobile Populations in the Dominican Republic</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Services International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

<b>Total All Funding Sources: 2,119,836</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,119,836</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,119,836

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17608
<b>Mechanism Name:</b>	Improving HIV/STI/TB Prevention, Treatment and Care Services for Mobile Populations in the Dominican Republic
<b>Prime Partner Name:</b>	Population Services International



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	159,950	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,014,222	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	448,120	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	497,544	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	44,813
PP_PREV_DSD	Total number of people in the target population	230,609
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	29,128
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	15,685
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,331
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	20,165
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	20,166
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	40,331
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	40,331
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,007



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,010
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	37,361
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	2,970
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	347
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	173
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	174
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	35
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	32
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	32
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	386
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	193
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	193
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	386
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	386
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	386
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	193
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	193
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	386
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	154
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	309
TX_PVLS_DSD	Numerator: Indication: Routine	154



TX_PVLS_DSD	Denominator: Indication: Routine	309
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	77
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	77
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	129
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	130

**Implementing Mechanism Details**

<b>Mechanism ID: 17752</b>	<b>Mechanism Name: RTI PHDP/Post-test Counseling</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17752</b>			
<b>Mechanism Name: RTI PHDP/Post-test Counseling</b>			
<b>Prime Partner Name: Research Triangle International</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17762</b>	<b>Mechanism Name: LINKAGES</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,418,747</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,418,747</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	1,418,747

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	400,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs



Gender: GBV	350,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Key Populations: FSW	400,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs

**Budget Code Information**

<b>Mechanism ID:</b>	17762		
<b>Mechanism Name:</b>	LINKAGES		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	130,043	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	457,103	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	200,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	631,601	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,429
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,715
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,714
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,429
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	7,429
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	200
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	196
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	7,429
GEND_GBV_DSD	Number of people receiving post-GBV care	9
GEND_GBV_DSD	Age/Sex: 20-24 Female	5
GEND_GBV_DSD	Age/Sex: 25-49 Female	4
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	9
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,234
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,119
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	1,115
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	224



TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	203
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	203
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,483
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,243
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,240
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,483
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,483
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	966
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	486
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	480
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	966
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,589
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,986
TX_PVLS_DSD	Numerator: Indication: Routine	1,589
TX_PVLS_DSD	Denominator: Indication: Routine	1,986
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	797
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	792
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	996
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	990
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,287
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,515



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	644
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	643
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	758
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	757

**Implementing Mechanism Details**

<b>Mechanism ID: 17915</b>	<b>Mechanism Name: Strengthening Strategic Information Capacity, Detection of HIV/TB Co-Infection and Clinical Services to Mobile Populations in the Dominican Republic</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 999,395</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 999,395</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	999,395



## Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17915		
<b>Mechanism Name:</b>	Strengthening Strategic Information Capacity, Detection of HIV/TB		
<b>Prime Partner Name:</b>	Co-Infection and Clinical Services to Mobile Populations in the Dominican Republic		
	Ministry of Health (MOH)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	125,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	674,395	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	726
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	726
TX_NEW_TA	By Age/Sex: 50+ Male	475
TX_NEW_TA	By Age/Sex: 50+ Female	474
TX_NEW_TA	Sum of Age/Sex disaggregates	949
TX_PVLS_TA	Number of adults and pediatric patients on ART with	9,131



	suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	10,981
TX_PVLS_TA	Numerator: Indication: Routine	9,131
TX_PVLS_TA	Numerator: Indication: Targeted	0
TX_PVLS_TA	Denominator: Indication: Routine	10,981
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	4,423
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	4,564
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	5,492
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	5,489
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	81
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	12
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	1
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1

## Implementing Mechanism Details



<b>Mechanism ID: 17916</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18388</b>	<b>Mechanism Name: GH13-1366, HQ, Strengthening and capacity building in resource constrained.</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 182,329</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 182,329</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	182,329

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18388		
<b>Mechanism Name:</b>	GH13-1366, HQ, Strengthening and capacity building in resource constrained.		
<b>Prime Partner Name:</b>	Clinical and Laboratory Standards Institute		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HLAB	182,329	0
------------------------	------	---------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
TX_PVLS_DSD	Numerator: Indication: Routine	1
TX_PVLS_DSD	Denominator: Indication: Routine	1
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	394
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	393
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	9,418
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	11,889
TX_PVLS_TA	Numerator: Indication: Routine	9,418
TX_PVLS_TA	Denominator: Indication: Routine	11,978
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	4,709
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	4,709
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	5,947
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	5,942
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	1
LAB_PT_TA	CD4: Number of laboratories that perform this testing	1
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories	12



	that participate in this PT program	
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	81
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1

**Implementing Mechanism Details**

<b>Mechanism ID: 18390</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18413</b>	<b>Mechanism Name: Health Finance and Governance (HFG)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	400,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18413			
<b>Mechanism Name:</b> Health Finance and Governance (HFG)			
<b>Prime Partner Name:</b> Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	400,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18414	<b>TBD:</b> Yes
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18461	<b>Mechanism Name:</b> UNAIDS III
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 200,000	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 200,000	
Funding Source	Funding Amount

Approved



GHP-State	150,000
GHP-USAID	50,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 18461</b>			
<b>Mechanism Name: UNAIDS III</b>			
<b>Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18462</b>	<b>Mechanism Name: SIFPO2</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 350,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 350,000</b>	



Funding Source	Funding Amount
GHP-USAID	350,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 18462			
<b>Mechanism Name:</b> SIFPO2			
<b>Prime Partner Name:</b> Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	350,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Agency Information - Costs of Doing Business  
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
ICASS			85,058	97,078	85,058	182,136
Non-ICASS Administrative			129,193	147,452	129,193	276,645



Costs						
Staff Program Travel		0	31,018	35,402	31,018	66,420
USG Staff Salaries and Benefits - Internationally Recruited		0	137,157	156,542	137,157	293,699
USG Staff Salaries and Benefits - Locally Recruited		0	144,944	165,429	144,944	310,373
<b>Total</b>	<b>0</b>	<b>0</b>	<b>527,370</b>	<b>601,903</b>	<b>527,370</b>	<b>1,129,273</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
ICASS		6,749		2,251	6,749	9,000
Indirect Costs		4,944		0	4,944	4,944
Staff Program Travel		3,387		1,612	3,387	4,999
USG Staff Salaries and Benefits - Locally Recruited		60,198		14,803	60,198	75,001



<b>Total</b>	<b>0</b>	<b>75,278</b>	<b>0</b>	<b>18,666</b>	<b>75,278</b>	<b>93,944</b>
--------------	----------	---------------	----------	---------------	---------------	---------------

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

<b>Agency Cost of Doing Business</b>	<b>GAP</b>	<b>GHP-State</b>	<b>GHP-USAID</b>	<b>Applied Pipeline</b>	<b>Total</b>	<b>Total All Cost of Doing Business Categories and Applied Pipeline Amount</b>
Capital Security Cost Sharing		52,000		0	52,000	52,000
Computers/IT Services		30,000		0	30,000	30,000
ICASS		190,000		0	190,000	190,000
Institutional Contractors		453,962		0	453,962	453,962
Non-ICASS Administrative Costs		606,758		0	606,758	606,758
Staff Program Travel		150,000		0	150,000	150,000
USG Staff Salaries and Benefits - Internationally Recruited	387,500	37,500		0	425,000	425,000
USG Staff Salaries and Benefits - Locally		578,645		0	578,645	578,645

Approved



Recruited						
<b>Total</b>	<b>387,500</b>	<b>2,098,865</b>	<b>0</b>	<b>0</b>	<b>2,486,365</b>	<b>2,486,365</b>